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The role of NMDA receptors in learning, memory and hippocampal function has
long been recognized. Post-mortem studies have indicated that the expression or
subunit composition of the NMDA glutamate receptor subtype might be related to
the impaired cognitive functions found in schizophrenia patients. NMDA receptor
antagonists have been used to develop animal models of this disorder. There is
accumulating evidence showing that not only the acute but also the chronic application
of NMDA receptor antagonists may induce schizophrenia-like alterations in behavior
and brain functions. However, limited evidence is available regarding the consequences
of NMDA receptor blockage during periods of adolescence and early adulthood.
This study tested the hypothesis that a 2-week treatment of male Long-Evans
and Wistar rats with dizocilpine (MK-801; 0.5 mg/kg daily) starting at postnatal
days (PD) 30 and 60 would cause a long-term cognitive deficit and changes in
the levels of NMDA receptor subunits. The working memory version of the Morris
water maze (MWM) and active place avoidance with reversal on a rotating arena
(Carousel) requiring cognitive coordination and flexibility probed cognitive functions
and an elevated-plus maze (EPM) was used to measure anxiety-like behavior. The
western blot method was used to determine changes in NMDA receptor subunit
levels in the hippocampus. Our results showed no significant changes in behaviors
in Wistar rats. Slightly elevated anxiety-like behavior was observed in the EPM in
Long-Evans rats with the onset of treatment on PD 30. Furthermore, Long-Evans rats
treated from PD 60 displayed impaired working memory in the MWM. There were;
however, no significant changes in the levels of NMDA receptor subunits because of
MK-801 administration. These findings suggest that a 2-week treatment starting on
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PD 60 in Long-Evans rats leads to long-term changes in working memory, but this deficit
is not paralleled by changes in NMDA receptor subunits. These results support the face
validity, but not construct validity of this model. We suggest that chronic treatment of
adolescent and adult rats does not constitute a plausible animal model of schizophrenia.
Keywords: schizophrenia, animal model, dizocilpine, rats, chronic treatment, western blot, behavior
INTRODUCTION
Schizophrenia is a devastating neuropsychiatric disease (Owen
et al., 2016), affecting all populations worldwide with a lifetime
prevalence of approximately 1%. Beside, to its well-known
symptoms, this disorder manifests with severe cognitive deficits.
Importantly, although cognitive deficits used to be viewed
as secondary symptoms, today they are considered the most
stable symptom class and provide the most rigorous basis
for predictions of long-term treatment outcomes (Elvevag and
Goldberg, 2000; Owen et al., 2016). It has long been suspected that
the glutamatergic system of the brain is involved in schizophrenia
(Kantrowitz and Javitt, 2012) because many glutamatergic
markers are altered in the brains of schizophrenic patients.
More recently, a decreased function of glutamate receptors in
schizophrenia has been combined with developmental concepts
involving changes in genetic and environmental contributing
to the disease to form a neurodevelopmental hypothesis of
schizophrenia (Davis et al., 2016).
As no direct causes or causal treatments for schizophrenia
are known, scientists often develop and evaluate animal models
of schizophrenia (Jones et al., 2011) as tools for investigating
mechanisms that may play a role in the actual disease and
to search for novel drugs with a better risk/benefit ratio.
Importantly, marked disruptions of behavioral functions similar
to those found in schizophrenia can be induced in animal models
using acute application of MK-801, a prototypical experimental
high-affinity non-competitive antagonist of NMDA receptors.
These include social deficits (low doses; Rung et al., 2005),
cognitive deficits (low-to-moderate doses; van der Staay et al.,
2011; Lobellova et al., 2013, Kubík et al., 2014; Svoboda et al.,
2015) and toxic and experimental psychoses (higher doses, Vales
et al., 2006; Lobellová et al., 2015). Chronic experiments aimed
at mimicking the neurodevelopmental abnormalities have shown
that these manipulations can also induce schizophrenia-like
behaviors. There is a large body of evidence in rats treated
with non-competitive NMDA receptor antagonists at an early
postnatal age (excellently reviewed by Lim et al., 2012). However,
relatively fewer studies have focused on the chronic effects of
NMDA receptor antagonism in subsequent ontogenetic periods
such as late adolescence or early adulthood, despite the fact that
schizophrenia in human patients manifests itself most commonly
in this age range (but see Li et al., 2011).
We hypothesized that repeated administration of MK-801
adolescent (starting on PD 30) and young adult rats (PD 60)
Abbreviations: ANOVA, analysis of variance; EPM, elevated-plus maze; MK-801,
dizocilpine maleate; MWM, Morris water maze; NMDA (receptors), N-methyl-D-
aspartate (subtype of glutamate receptors); PCP, phencyclidine; PD, postnatal day;
SEM, standard error of the mean; TBS, Tris-buffered saline.
would result in cognitive disturbances and changes in the levels
of NMDA receptor subunits in the hippocampus, a region crucial
for these functions and critically involved in schizophrenia. We
sought to remedy knowledge gap on this time of treatment
and test phenomenological (changes in behavior) and construct
(changes in NMDA receptor subunits) axes of validity of this
model.
MATERIALS AND METHODS
Animals
We use two common outbred rat strains, Wistar and Long-
Evans. Male rats of Wistar (n = 32) and Long-Evans (n = 40)
strains were obtained from the breeding colony of the Institute
of Physiology of the Czech Academy of Sciences (IPHYS). They
were housed in 25 cm × 30 cm × 40 cm plastic transparent
cages in groups consisting of 2–4 animals in an air-conditioned
animal room with constant temperature, humidity and a 12/12 h
light/dark cycle. The rats were weaned at PD 28. Access to food
and water was always ad libitum. All animal manipulations were
approved by the Ministry of Agriculture committee and done
according to the approved project of experiments no. 136/2013.
The procedures complied with the Animal Protection Code of
Czechia and the appropriate directive of the European Union
(2010/63/EC).
Drugs
MK-801 (dizocilpine maleate) was obtained from Sigma–Aldrich,
Czechia. The drug was dissolved in saline at a concentration of
0.5 mg/ml and injected subcutaneously in the skin fold between
the shoulders at a dose of 0.5 mg/kg body weight. Control groups
received subcutaneous injections of saline at a volume of 1 ml/kg.
Injections were administered between 10 am and 11 am for 14
consecutive days.
Design of Study
For behavioral testing, we employed a working memory version
of the MWM (Vales et al., 2006) with 15-s intervals between
swims. Active place avoidance with reversal on a rotating arena
(Carousel) was used to test cognitive coordination and flexibility
(for review see Stuchlík et al., 2013). For assessment of anxiety-
like behavior, we used an EPM. Notably, working memory,
cognitive coordination and behavioral flexibility are markedly
disrupted in patients with schizophrenia (Elvevag and Goldberg,
2000; Owen et al., 2016). Moreover, we analyzed levels of protein
for NMDA receptor subunits in the hippocampus. We detected
the GluN1, GluN2A, and GluN2B subunits by western blot
analyses to assess changes in their expression.
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Animals from each strain were injected with MK-801 starting
at two ages: PD 30 or PD 60. Age-matched controls were
given saline. All Long-Evans groups consisted of 10 animals. All
Wistar groups consisted of eight animals. Animals were assigned
to treatment groups randomly prior to start of experiments.
Long-Evans and Wistar rats were tested in two different
runs, separated by a 2-month interval; therefore, no direct
comparisons of behavioral parameters between those two strains
were performed.
Injections were separated by 24 h. Upon completing the
injections, animals were left undisturbed for 5 days in their
home cages to stabilize their behavior and for the drug to wash
out, to prevent acute side effects from affecting the results. The
behavioral tests were performed in the following sequence: the
EPM, the working memory version of the MWM, and active
place avoidance with reversal (Figure 1). At the age of 3 months,
animals were decapitated in isoflurane anesthesia and both right
and left hippocampi were dissected and prepared for western blot
analysis of the levels of NMDA receptor subunits (see the section
Bioanalytical Analysis below).
Behavioral Tasks
Elevated Plus Maze
The EPM is a gold standard for testing anxiety-like behavior in
rodents (Haller et al., 2013). Many patients with schizophrenia
report increased anxiety possibly do to the presence of positive
symptoms (Temmingh and Stein, 2015), that is why we used
this test as a part of behavioral battery aiming at face validity of
chronic treatment with MK-801.
The EPM was a test of unconditioned avoidance behavior that
involved four narrow arms elevated one meter above the floor
of a dimly lit experimental room. A standard elevated plus maze
apparatus was used (Pellow et al., 1985). Two opposite arms were
enclosed by walls and the remaining arms were open. In the
standard 5-min version of the test, rats spent more time exploring
the enclosed arms than the open. Each rat was placed in the center
of the maze with the head pointing toward the closed arms, and
was then allowed to move freely for 5 min. Viewer (Biobserve)
and Ethovision (Noldus) software was used to quantify behavior.
The EPM test was administered on PD 49 in animals with the
onset of treatment on PD 30, and on PD 78 in animals treated
from PD 60 (Figure 1).
Working Memory Version of the Morris Water Maze
The working memory version of the MWM (Vales et al., 2006)
permits the study of spatial working memory encoded by a
single learning trial (the first swim in each session). Working
memory deficit constitutes a strong and reliable phenotype
for schizophrenia (Forbes et al., 2009) and reaches spatial
domain (Fajnerová et al., 2014). We therefore used this task
as a component of battery assessing face validity of chronic
MK-801 model. The MWM was performed over 10 daily sessions
consisting of four swims (trials) to a hidden platform, with a delay
of 15 s between trials. The platform position was changed daily in
a pseudorandom order. Each day, the platform was in a unique
location; there was to interference between the sessions. Release
positions were pseudo-randomized by the partial Latin square
method. The MWM was administered from PD 50 in the younger
age cohort and from PD 79 in the older age cohort (Figure 1).
Active Place Avoidance on a Rotating Arena
(Carousel)
Active place avoidance with reversal in Carousel is a test of
cognitive coordination and behavioral flexibility. The task has
been repeatedly validated (Bures et al., 1997; Fenton et al., 1998;
Czéh et al., 2001; Stuchlik and Bures, 2002; Wesierska et al.,
2005; Kubík et al., 2006; Stuchlik and Vales, 2006; Petrasek
et al., 2014a,b; for review see Stuchlík et al., 2013) and a typical
dynamic-environment test (Stuchlik, 2014; for comparison, see
Telensky et al., 2011). To our best knowledge, no other test
places demands for coordinating two reference frames (arena and
room frame). Cognitive coordination is significantly disrupted
in schizophrenia (Phillips and Silverstein, 2003); therefore, the
selection of this task was justified in this study. The testing
consisted of 10 sessions (all separated by 24-h intervals). The
initial five sessions were considered as acquisition sessions (with
the to-be-avoided sector in arbitrary North), which were followed
by five reversal sessions, with the sector position shifted by 180
degrees (arbitrary South). This shift made the task sensitive not
only to cognitive coordination, but also to cognitive flexibility
(Burghardt et al., 2012; Lobellova et al., 2013; Svoboda et al.,
2015). Carousel maze testing was conducted during daylight
hours (10 am – 4 pm).
The rotating arena (Carousel) (invented by Fenton et al.,
1998 and originally described by Bures et al., 1997) was a
smooth metallic arena (82 cm in diameter), enclosed with a
50-cm transparent Plexiglas wall (for details of the apparatus
and procedures see Stuchlík et al., 2013). Prior to testing,
conscious rats were gently implanted with a hypodermic needle,
piercing the skin fold on the animal’s back. The sharp end of
needle was blunted and a small loop was created with tweezers,
preventing the needle from slipping out and providing purchase
for an alligator clip, which delivered mild electric shocks (see
below). The needle implantation corresponded to subcutaneous
injection in humans and did not require anesthesia. At the
beginning of each session, a rat was placed on the arena, which
rotated constantly at one revolution per minute. A 60-degree
to-be-avoided sector was defined in the coordinate frame of the
room by a computer-based tracking system (Tracker, Biosignal
Group, United States), which also recorded the positions of
the rat and the arena (which were both marked by infrared
LED diodes) at a sampling rate of 25 Hz. Each entrance into
the sector lasting more than 300 ms was punished by mild
constant-current footshocks (repeated every 1200 ms until the rat
left the sector) delivered by the tracking system. The intensity of
the shock was individualized for each rat (0.2–0.6 mA), to ensure
an escape reaction while avoiding freezing. Most rats responded
appropriately to 0.2 or 0.4 mA. The footshocks were administered
through a cable attached to a harness on the back of the rat
and connected to the conductive subcutaneous implant. This
level of shock intensity is set to be unpleasant for rats, but not
painful; in the latter case, the footshock application would elicit
freezing, which would have prevented the avoidance learning.
Therefore, we kept the footshock on minimal possible level.
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FIGURE 1 | Schematic diagram of the experimental design.
The trajectories were digitized and recorded on a PC, allowing
the off-line reconstruction and analysis of the animal’s trajectory
and avoidance behavior with Track Analysis software (Biosignal
Group, United States). Further detailed analysis and verification
of the data was done in the open-source software Carousel Maze
Manager (Bahník, 2014). Testing in the Carousel was conducted
from PD 60 in the younger age cohort and from PND 89 in the
older age cohort (Figure 1).
Bioanalytical Analysis
Western blot analysis was performed to determine changes in
the concentration of subunits of the NMDA receptor, measuring
the levels of protein expression for the GluN1, GluN2A, and
GluN2B subunits. Tissue from the left and right hippocampi
was collected from both the Wistar and Long-Evans rats, frozen,
and stored at −80◦C until analysis. Next, all samples were
homogenized using a series of ultrasonic pulses (50% of max.
amplitude, duration 500 ms, 8 pulses per sample; UP100H,
Hielscher) with 10 mM PBS (pH 7.4) at a ratio of 1:9 and
protease inhibitor cocktail (#P8340, Sigma–Aldrich). Obtained
homogenates were centrifuged (#120951, SIGMA 2-16 PK) at
1000 g for 10 min at 4◦C and the supernatant was collected.
A small volume of the hippocampus lysate was used for the
quantification of protein concentrations by the Lowry method
(Lowry et al., 1951) with Peterson’s modification (Peterson,
1977).
Before electrophoresis, samples were mixed with Laemmli
loading buffer (#161-0737, Bio-Rad, Hercules, CA, United States)
and heated for 20 min at 70◦C. Stain-Free gradient gels
(#567-8084, Bio-Rad, Hercules, CA, United States) were used for
protein separation. The samples were subsequently transferred
to nitrocellulose membranes (#170-4271, Bio-Rad) using a
Trans-blot Turbo apparatus (Bio-Rad, United States). The quality
of transfer and volume of protein on the membrane were
determined by a ChemiDocTM Touch Imaging System (Bio-Rad,
United States). Membranes were blocked in 5% non-fat milk in
TBS overnight. On the subsequent day, membranes were first
incubated with either the primary antibodies anti-GluN1 1:1000
(NeuroMab clone N308/48), anti-GluN2A 1:500 (NeuroMab
clone N327/95) or anti-GluN2B 1:1000 (NeuroMab clone
N59/36), and then washed 3x 10 min in TBS. Then, membranes
were incubated for 2 h at room temperature with secondary
antibody at 1: 30 000 (#115-035-174, Jackson ImmunoResearch
Laboratories, Baltimore, PA, United States) for 1 h (RT) and
washed with TBS as described above. A chemiluminescent
substrate (Supersignal West Femto, #34096, Thermo Scientific,
Waltham, MA, United States) was used for the visualization of
protein with the ChemiDocTM Touch Imaging System (Bio-Rad,
United States). The bands were detected and analyzed with
ImageLab software. (Bio-Rad, United States). Stain-free images of
total protein were used for normalization of the target proteins as
described previously (Tramutola et al., 2016). When performing
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normalization, detection of a housekeeping protein (for example,
actin, tubulin, GAPDH) or total protein in the lines can be
used. However, housekeeping proteins can vary in different
tissues, at different ages, but also because of experimental
manipulations (Fukazawa et al., 2003; Li and Carmichael, 2006).
For these reasons, we chose normalization to total protein.
The above-mentioned stain-free method was used to determine
the total protein in the lanes. The principle of the method is based
on modification of the tryptophan amino acid by the compound
trihalo, resulting in a very marked increase in fluorescence after
activation by UV light. This method is comparable to protein
staining with SYPRO Ruby, Coomassie Blue or silver stain (Gilda
and Gomes, 2013). For illustration, see the stain-free images in
Supplementary Material.
Data Analysis and Statistics
Analysis of the Behavioral Parameters
In the elevated plus-maze, the following parameters were
measured: time spent in the open arms, closed arms, and central
platform, head dipping and risk assessments (the latter two are
not reported, as no effects were seen). In the MWM, latency
and total distance to reach the platform were recorded. In
the Carousel, we measured the number of entrances into the
to-be-avoided sector (number of errors) and total distance walked
during a session (computed as the cumulative total distance of
data points measured at 1-s intervals; this sampling eliminates
non-locomotor movements such as shivering). We also recorded
the maximum time between two entrances (maximum time
avoided) and the latency to the first entrance to the to-be-avoided
sector in a given session (latency to the first error). However, since
these parameters generally correlate highly with the number of
errors, their analysis did not provide any additional information
value; these data are not included here. In all these behavioral
experiments, statistical analyses were performed separately for
each strain as both strains were testing in separate batches.
Data from the elevated plus-maze were assessed using two-way
ANOVA with age and MK-801 treatment as main factors.
To avoid three-way ANOVAs in water maze and active place
avoidance in which repeated measures add another factor of
complexity, we selected a parameter that well characterizes the
extent of learning. In water maze, we summed the latency and
total distance from swims 2 to 4 and averaged them across
the 10 days of training. In active place avoidance, we summed
number of entrances and total distance across the 5 days of
acquisition. We also evaluated these two parameters in 1st day
of reversal when they best reflect behavioral flexibility. Two-way
ANOVA was conducted with treatment (MK-801, saline) and
age (PD30, PD60) as the main factors. When appropriate,
ANOVA was followed by Sidak’s post hoc test. All calculations
were performed using GraphPad Prism 7.0, with a level of
acceptance set at P < 0.05. Data are reported in the figures as
means± SEM.
Analysis of Biochemical Parameters
Images of target proteins and stain-free images of total protein
were created on the ChemiDocTM Touch system and analyzed
in ImageLab. The values were taken from the left and right
hippocampi, but since there were no differences between them,
they were pooled together for subsequent analyses. The measured
values were tested for outliers by calculating a z score, and
consequently the values having a z score greater than 2 were
excluded. We used 14–16 samples in each group. For statistical
analysis we used Statistica 9 (StatSoft) and graphs were created
using GraphPad Prism 5.0. Differences between groups were
evaluated by a two-way ANOVA with treatment and age
as independent factors; statistically significant differences are
reported at P < 0.05. Data are reported as means ± SEM total
protein normalized intensity.
RESULTS
Repeated Administration of MK-801
Causes Severe Qualitative Acute and
Long-term Effects
In both strains, both age groups of rats administered with
0.5 mg/kg MK-801 displayed acute behavioral changes as
expected. Since 0.5 mg/kg is a relatively high dose, we
observed the onset of restlessness 5 min after application
followed by hyperactivity (running near the wall, sniffing
in the corners, salivation) and motor disturbances (inability
to stand upright, falling and crawling). Some rats were
hypoactive and even had signs of ataxia. This type of behavior
typically diminished 1–2 h after MK-801 administration.
One week after injection, three Long-Evans rats exhibited
increased aggressiveness, and therefore were placed in cages
separately and were not included in behavioral and bioanalytical
testing.
Behavioral Results
Repeated MK-801 Led to Mild Long-term
Anxiety-Like Behavior in Adolescent Long-Evans
Rats
Wistar rats
Data obtained in the EPM suggests that MK-801 exerted no
effects on anxiety-like behavior in Wistar rats. As Figure 2
illustrates, there was no difference between saline and MK-801
injected groups in neither age when evaluating the time spent in
the center [F(1,28)= 2.988], open arms [F(1,28)= 0.01] or closed
arms [F(1,28)= 1.577]. However, on average PD30 rats spent less
time in the center than PD60 rats [effect of age: F(1,28) = 6.125,
P = 0.0196].
Long-Evans rats
When analyzing behavior of Long-Evans rats, we found
significant effect of MK-801 in the time spent in closed arms
[F(1,36) = 5.737, P = 0.0219] and significant age vs. treatment
interaction in time spent in the center [F(1,36) = 8.259,
P = 0.0068]. Post hoc tests revealed it was due to different effects
in PD30 groups. These results indicate elevated anxiety-like
behavior in Long-Evans rats in the younger age cohort. On the
other hand, time spent in open arms was not affected by MK-801
treatment in Long-Evans rats [F(1,36)= 1.556, P = 0.2204].
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FIGURE 2 | Performance in the elevated plus maze evaluated by total time
spent in the central part (A), open arms (B), and closed arms (C). Comparing
MK-801 and saline-treated rats in each cohort yielded significant differences
only for PD 30 Long-Evans rats in entering the center, and for PD 30
Long-Evans rats in entering the closed arms. Group means ± SEM
(∗P < 0.05, ∗∗P < 0.01).
Repeated MK-801 Induced Long-term Impairments
of Working Memory in Adult Long-Evans Rats
Wistar rats
To quantify performance in the working memory version of
the MWM, we summed the latency and total distance from
swims 2 to 4 and averaged them across the 10 days of training.
As can be seen in Figure 3, MK-801 elicited no effects in
Wistar rats. Two-way ANOVA failed to find an effect of MK-801
[latency: F(1,28) = 0.8502, P = 0.36; distance: F(1,28) = 0.8165,
P = 0.37] and age [latency: F(1,28) = 0.008, P = 0.93; distance:
F(1,28)= 0.056, P = 0.82].
Long-Evans rats
In contrast, pattern in Long-Evans rats was more complex.
Analyzing latency, two-way ANOVA failed to see an effect of
MK [F(1,30) = 0.96, P = 0.33] but showed main effect of age
[F(1,30) = 10.52, P = 0.003] and interactions [F(1,30) = 7.99,
P = 0.008]. Then Sidak’s post hoc test confirmed significantly
increased latency in MK-801-treated PD 60 rats compared to
PD 60 controls. Similar results were obtained when analyzing
path: Main effect of MK-801 [F(1,33) = 4.13, P = 0.05], age
[F(1,33) = 0.39, P = 0.54], and interaction [F(1,33) = 7.71,
P = 0.009]. Subsequent post hoc test confirmed elevated path in
PD 60 MK-801 rats compared to PD60 controls.
Repeated MK-801 Failed to Induce Deficits in
Acquisition and Reversal Learning in the Carousel
Number of errors (entrances) reflects the ability of properly
locating the to-be-avoided place on the arena. We summed
number of entrances across the five sessions of acquisition to get
an overall parameter of acquisition. Then we analyzed data from
first reversal session as this time point allows for evaluating the
ability of cognitive flexibility.
Wistar rats
Despite Figure 4 indicates that PD 60 Wistar rats accumulated
lower number of entrances during acquisition, two-way ANOVA
failed to see an effect of age [F(1,28) = 3.534, P = 0.07].
Furthermore, there was neither effect of MK-801 administration
[F(1,28) = 0.3092, P = 0.58] nor significant treatment vs.
age interaction – [F(1,28) = 0.175, P = 0.6789]. Similarly,
cognitive flexibility as measured by number of entrances
in the 1st day of reversal was not affected by MK-801
administration in Wistar rats [F(1,33) = 0.013, P = 0.91] or
age [F(1,28) = 3.534, P = 0.0706]; interaction [F(1,28) = 0.175,
P = 0.6789].
Long-Evans rats
As Figure 4 illustrates, Long-Evans rats performed equally
during acquisition at both ages [F(1,33) = 2.723, P = 0.11]
despite MK-801 administration [F(1,33) = 0.01319, P = 0.9093]
measured by a summed number of entrances during acquisition.
Surprisingly, a two-way ANOVA found a significant effect of
age [F(1,33) = 8.782, P = 0.0056] and effect of age vs. MK-801
interaction [F(1,33) = 3.973, P = 0.05] in the 1st day of reversal
resulting from decreased number of entrances in Long-Evans
rats treated with MK-801 from PD 60 (Sidak’s post hoc test,
P= 0.03). Besides the number of entrances, we also evaluated the
total distance moved during a session to investigate the effects of
repeated administration of MK-801 on overall locomotion, but
two-way ANOVA did not reveal a significant effect of MK-801
or age in any experimental condition in either strain or any
cohort.
Repeated MK-801 Failed to Affect the
Levels of NMDA Receptors Subunits in
the Hippocampus
Table 1 shows the mean of values of protein concentrations
(µg/µl). Hippocampal expression of NMDA subunits (GluN1,
GlunN2A, and GluN2B) was analyzed for both strains
independently with using a two-way ANOVA (see Figures 5, 6).
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FIGURE 3 | Latency and path to the platform (distance) in the water maze summed for swim 2, 3, and 4, and averaged across the 10 days of training. In the
Long-Evans PD 60 cohort, MK-801 treated rats did not search for the platform on repeated swims as efficiently as saline treated rats (∗P < 0.05, ∗∗P < 0.01). Group
means ± SEM.
Wistar Rats
Analysis of expression of NMDA receptor subunits in Wistar
rats showed no significant changes. Expression of GluN1 showed
no significant main effects of treatment group [F(1,60) = 0.113,
P = 0.738] and age [F(1,60) = 2.556, P = 0.11723] neither
age × treatment of interaction [F(1,60) = 0.141, P = 0.709].
Expression of GluN2A showed no significant changes main
effects of age [F(1,60) = 2.5006, P = 0.11906] and treatment
[F(1,60)= 0.8581, P= 0.358] neither age× treatment interaction
[F(1,60)= 0.2149, P= 0.6447]. Expression of GluN2B showed no
significant main effects, treatment [F(1,60) = 0.185, P = 0.668]
and age [F(1,60) = 0.083, P = 0.775], neither interaction
treatment× age [F(1,60)= 2.889, P = 0.094].
Long-Evans Rats
Expression of GluN1 subunits in Long-Evans rats showed
no significant main effect of treatment [F(1,58) = 0, 41,
P = 0.524], but a significant main effect of age for administration
[F(1,58) = 10.062, P = 0.002] and significant effect of
treatment× age interaction [F(1,58)= 6.4068, P= 0.014]. Tukey
post hoc test showed a significant decrease of GluN1 between
PD 30 and PD 60 groups with MK-801 (P = 0.0013) and
between control group PD 30 and MK-801 PD60 (P = 0.049).
Expression of GluN2B showed no significant main effects of age
[F(1,52) = 2.6417, P = 0.11014] and treatment [F(1,52) = 0.375,
P = 0.543], but a significant treatment × age interaction
[F(1,52) = 6.1454, P = 0.01646]. Tukey post hoc test showed a
decrease of GluN2B between PD 30 and PD 60 after MK-801
administration (P = 0.045). Expression of GluN2A showed
no significant main effect of treatment [F(1,52) = 0.298,
P = 0.588], age [F(1,52) = 0.014, P = 0.907], or interaction
[F(1,52) = 0.80640, P = 0.37333]. However, not significant
differences between MK-801- and saline-treated PD 30 and PD
60, respectively, Long-Evans rats were found.
DISCUSSION
General Remarks
In this study, we evaluated the effects of a 2-week repeated
treatment with the NMDA antagonist MK-801 given in
the adolescent and early adulthood periods in Wistar and
Long-Evans rats. We detected an elevation of anxiety-like
behaviors, measured by time spent in the center and closed arms
but not open arms of the elevated plus maze, in Long-Evans
rats treated with MK-801 from an adolescent age. Moreover,
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FIGURE 4 | Performance in active place avoidance evaluated as the summed number of entrances into the to-be-avoided sector during 4 days of acquisition (left
graphs) and 1st day of reversal (right graphs). Differences between MK-801 and saline treated rats were statistically significant only during reversal in the Long-Evans
PD 60 cohort, with MK-801 administered rats to be superior to saline controls (∗P < 0.05). Group means ± SEM.
we found a significant impairment of working memory tested
in the MWM in Long-Evans rats treated at the early adult
age (from PD 60). No differences were found in cognitive
learning and flexibility tested in the Carousel. There were also
no significant changes in the expression of NMDA receptor
subunits because of MK-801 in any strain and age. Acute
administration of NMDA receptor antagonists is used by
recreational drug users and in animal models and it can mimic
TABLE 1 | Mean of total protein concentration in samples for Western blot
analyses.
Groups Concentration of
proteins in
samples (µg/µl)
Count of samples
Mean SEM
Wistar Control PD 30 7.56 0.31 n = 16
Control PD 60 8.02 0.13 n = 16
MK-801 PD 30 7.57 0.35 n = 16
MK-801 PD 60 9.18 0.25 n = 16
Long-Evans Control PD 30 7.48 0.30 n = 20
Control PD 60 6.23 0.34 n = 20
MK-801 PD 30 6.90 0.36 n = 18
MK-801 PD 60 5.42 0.49 n = 10
Data was obtained by using a modificated Lowry’s method.
some aspects of psychosis. Abuse of NMDA antagonists in
adolescence is associated with higher overall effect, risks for
developing psychosis and dependence compared to adult use in
human subjects. This notion was demonstrated in rats too (Rocha
et al., 2017) where adolescent rats displayed more pronounced
behavioral activation to single dose of PCP and ketamine.
Contrarily, repeated intermittent dosing of these drugs showed
more pronounced sensitization effect in adults than in adolescent
rats.
Chronic administration of MK-801, PCP and ketamine
in rodent models are currently used to achieve long-term
changes in behavior and neurotransmission. Abdul-Monim
et al. (2006) reported that female rats trained to solve a
simple task failed to complete the task again after chronic
PCP administration. Further, the administration of atypical
antipsychotics (ziprasidone, olanzapine, clozapine) improved
performance, but classical antipsychotics did not have the same
beneficial effect (Abdul-Monim et al., 2006). In another study,
rats performed significantly worse in the MWM 2 weeks after
subchronic MK-801 administration, and at the same time did not
differ in weight or locomotor activity (Li et al., 2011).
Behavioral Changes after Repeated
MK-801 Administration
No clear effects on anxiety, working memory, or spatial learning
were detected in Wistar PD 30 or PD 60 rats given MK-801
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FIGURE 5 | Expression of NMDA subunits in the hippocampus: (A) GluN1 subunit, (B) GluN2A subunit (C) GluN2B subunit: The charts show the two intervals of the
start of administration (PD 30 and PD 60). Strains of rats are marked as Long-Evans (LE) and Wistar (W). The data show the mean level of chemiluminescence after
total protein normalization (group means ± SEM). #P < 0.05 compared to controls of the same strain and age. ∗P < 0.05, ∗∗P < 0.01; comparison between age
cohorts.
for 2 weeks. In contrast, Long-Evans rats were more affected by
this treatment. Our results show that Long-Evans rats from the
older age group, i.e., PD 60 at the onset of treatment display
cognitive impairments, whereas adolescent Long-Evans rats are
susceptible to elevations in anxiety-like behaviors, induced by
chronic NMDA receptor antagonism.
Anxiety-Like Behavior
We did not detect any alterations in anxiety-like behavior in
Wistar rats. Long-Evans rats administered MK-801 on PD 30
displayed higher anxiety levels in the EPM by spending more
time in the closed arms than the control group. However, there
was no significant change in the time spent in open arms. Studies
on long-term changes in anxiety-like behavior due to MK-801
and other glutamatergic psychotomimetics are rather scarce. In
contrast to the increased anxiety in PD 30 Long-Evans rats found
in this study, Kocahan et al. (2013) and Latysheva and Rayevsky
(2003) found decreased levels of anxiety-like behavior in the EPM
in Wistar rats treated from PD 7 to PD 10 with 0.25 mg/kg and
from PD 7 to PD 49 with 0.05 mg/kg. However, Baier et al.
(2009) reported increased anxiety-like behavior on PD 90 in the
EPM in Wistar rats after 0.25 mg/kg of MK-801 administered
from PD 6 to PD 21. These discrepancies are likely caused by a
different dose and timing of applications, but our results imply
a susceptibility to elevated anxiety in Long-Evans rats treated in
adolescence.
Spatial Working Memory in the MWM and Cognitive
Learning in the Carousel
Interestingly, testing in the MWM revealed an impairment
of working memory only in older PD 60 MK-801-treated
Long-Evans rats compared to saline-treated subjects. Rats given
MK-801 were still able to learn the task but at a slower rate.
Active place avoidance testing did not reveal any difference
between MK-801-treated and saline-treated rats 30 days after
application, with no effects found on cognitive coordination
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FIGURE 6 | Examples of Western blot of the hippocampal supernatant
showing expression of the NMDA subunits (GluN1 ∼100 kDa,
GluN2A∼170 kDa, GluN2B ∼180 kDa) at two age intervals (PD 30, PD 60) in
Long-Evans and Wistar rats. Control group samples are in columns 1–4 and
MK-801 samples are in the columns 5–8.
and flexibility. It should be noted that overall performance
of both control and MK-801 rats (Vales and Stuchlik, 2005;
Stuchlik et al., 2008), which implies that chronic stress caused
by injections in all groups may have negatively affected their
performance.
Previously published studies have reported contrasting effects
of chronic MK-801 treatment in the postnatal and early
adolescent periods on cognition in the spatial and non-spatial
domains. McLamb et al. (1990) observed no impairment in a
water maze after 0.2 mg/kg MK-801 treatment administered
from PD 9 to PD 15 in Fisher-344 rats. Kocahan et al. (2013)
failed to find any deficit in an inhibitory avoidance task in
Wistar rats treated in the early postnatal age and tested at
adolescence (application: PD 7 – PD 10; testing at PD 35 – PD
45). Rats treated two times a day for 7 days with 0.5 mg/kg
MK-801 in adulthood were not affected by the treatment in
a variable-delayed alternation task or in a T-maze 36 h after
administration (Seillier and Guiffrida, 2009). However, other
studies have shown clear impairments in spatial memory after
chronic MK-801 application, further supporting our data. After
0.25 mg/kg MK-801 given from PD 8 to PD 19, Wistar rats
displayed a slower learning rate in a water maze task in
adulthood (Gorter and de Bruin, 1992). Latysheva and Rayevsky
(2003) treated Wistar rats with 0.05 mg/kg MK-801 from PD
7 to PD 49, and found impaired performance in a complex
maze 5 days after treatment. Kawabe and Miyamoto (2008)
found impairment in a delayed non-matching-to-position task in
adulthood after 0.2 mg/kg and 0.4 mg/kg MK-801 applications
two times a day from PD 7 to PD 20 in Wistar rats. In
mice, 0.1 mg/kg MK-801 treatment administered from PD 3
to PD 17 worsened performance in the MWM (Elhardt et al.,
2010). Finally Li et al. (2011) observed a disruption of spatial
working memory in the MWM after 2-week administration
OF MK-801 to adolescent Sprague-Dawley rats (starting on
PD 28), further indirectly supporting our data although with
a different age and strain. Again, different doses and time of
administration precludes direct comparison or data of ours and
other authors, but the results show a spatial working memory
deficit due to MK-801 treatment in young adult Long-Evans
rats, supporting the face validity of this treatment in this
strain.
Locomotor Activity
We did not observe hyperlocomotion in the MWM or active
place avoidance after repeated MK-801 treatment, though such
an effect has been seen after the acute administration of the
same dose (Hargreaves and Cain, 1995; Lobellova et al., 2013;
Svoboda et al., 2015). Hyperlocomotion is thought to correlate
with the positive symptoms of schizophrenia and is one of
the well-characterized effects of chronic MK-801 treatment
(Lim et al., 2012). Kocahan et al. (2013) observed increased
spontaneous locomotor activity in an open-field test in Wistar
rats after 0.25 mg/kg MK-801 given from PD 7 to PD 10.
Facchinetti et al. (1993) also observed hyperlocomotion in
an open-field test in Wistar rats after the administration of
increasing 0.5 – 1 mg/kg doses from PD 1 to PD 22, and this
increased activity lasted until PD 60. After 0.25 mg/kg MK-801
administered from PD 6 to PD 21, Schiffelholz et al. (2004)
detected increased spontaneous activity on PD 30, but from
PD 60 rats displayed hypolocomotion lasting until PD 180. In
contrast, however, numerous other authors have reported no
effects of early-life MK-801 treatment on spontaneous locomotor
activity in rats (Stefani and Moghaddam, 2005; Kawabe et al.,
2007; Uehara et al., 2009). McLamb et al. (1990) reported no
effects of 0.2 mg/kg MK-801 administered from PD 9 to PD
15 in Fischer-344 rats on locomotor activity in the MWM.
The absence of locomotor changes in our model suggests
that it does not constitute a model of positive symptoms of
schizophrenia.
Effects of Repeated Administration of
MK-801 on NMDA Receptor Subunits
We did not detect any significant changes in the expression of
GluN1, GluN2A, or GluN2B subunits in MK-801-treated Wistar
or Long-Evans rats compared with control groups. We only
observed differences between different times of administration
of MK-801. In accordance with our data, Wang et al. (1999)
failed to detect any change in GluN1 subunit expression in the
hippocampus of rats chronically administered with PCP, and
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only found an increase in the GluN1 subunit in the forebrain.
Chronic PCP given to adult mice resulted in an increased number
of binding sites for MK-801 shortly after treatment (Newell
et al., 2007). However, 14 days after treatment the number
of MK-801 binding sites decreased significantly, especially in
the hippocampus. These results are in partial accordance with
our present data. However, Oh et al. (2001) reported increased
numbers of the GluN1 subunit in CA1 of the hippocampus
after intracerebroventricular infusion with MK-801 in Sprague-
Dawley rats. Anastasio and Johnson (2008) reported an increased
number of GluN1 and GluN2B subunits induced by translocation
from the endoplasmic reticulum to the membrane after acute
PCP administration. In contrast, repeated administration of PCP
led to the increased de novo synthesis of NMDA subunits.
It has to be pointed out that the amounts of protein for
NMDA receptor subunits might not be equal to the number of
active receptors, which may contributed to the negative findings
reported in this study. The changes between Long-Evans rats
treated from PD 30 vs. PD 60 may have been a result of
different brain responses in relation to the age of the rats during
the administration of MK-801. Matta et al. (2013) described
the disruption of developmental changes in NMDA receptors
induced by giving MK-801 during ontogenesis. Age-dependent
differences may also occur due to different NMDA currents in
immature neurons compared to fully mature neurons and due
to the different ontogenetic development of individual structures
(Wang and Gao, 2009; Rotaru et al., 2011; Nakazawa et al.,
2017). GluN2B and GluN2A subunits of the NMDA receptor
show varied expression during ontogenetic development. The
GluN2B subunit is most highly expressed in the first PDs and its
concentration gradually decreases, while GluN2A concentrations
are low after birth and gradually rise until PD 21, when they
reach levels comparable with those in adulthood (Wenzel et al.,
1997). Our finding that in MK-801-treated animals the levels
of GluN1 and GluN2B are changed due to age of treatment
most likely represent the developmental changes in sensitivity of
NMDA receptor system to this drug. The absence of MK-801-
induced effects also decreases the construct axis of validity of this
model.
Limitations of the Study
This study has a few limitations. Notably, both strains were
testing in different batches as mentioned in the section
“Materials and Methods,” preventing their direct comparison. In
addition, both age cohorts underwent their behavioral testing
at different periods of their development (PD 49 – PD 69 vs.
PD 78 – PD 97), but intended to keep the interval between
administration of the drugs and behavioral testing constant
to allow for comparison. Repeated drug administration in
the adolescent period raises concerns regarding the correct
physical development of the animal. However, in this study,
rats treated with MK-801 did not differ in total health status
or reactions to environmental stimuli during behavioral testing
(visual observations; data not shown) except the three rats
that exhibited aggressiveness that were excluded from the
study.
CONCLUSION
Chronic treatment with the NMDA antagonist MK-801 impaired
working memory only in Long-Evans rats treated in early
adulthood with application starting from PD 60. Suggestively
elevated anxiety was found in Long-Evans rats treated at
adolescent age. This data support the face validity of this
treatment as potential animal model of cognitive deficits due to
chronic experimental psychosis. However, no significant effects
were observed in expression of NMDA subunits by Long-Evans
or Wistar strains at any age. These finding did not support the
construct validity of this model. In conclusion, our results suggest
that despite a working memory deficit and elevated anxiety in one
of the strains, this dose, timing and period of treatment with MK-
801 does not constitute a plausible model of schizophrenia-like
phenotypes.
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